Tessera
Folgen

Michelle Lockley

@mlockley.bsky.social

Medical oncologist and scientist, into all things ovarian cancer. In search of the answer to cancer drug resistance

3 Posts533 Follower423 Folgt
Trevor Graham@trevorgraham.bsky.social · last yr.

With the brilliant @mlockley.bsky.social we've been exploring chemo resistance evolution in ovarian cancer. We find resistance has a fitness cost which means resistant cells are outcompeted by sensitive cells when treatment is stopped. aacrjournals.org/cancerres/ar... @icr.ac.uk @qmbci.bsky.social

Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control

Abstract. Drug resistance results in poor outcomes for cancer patients. Adaptive therapy is a potential strategy to address drug resistance that exploits competitive interactions between sensitive and...

aacrjournals.org

Trevor Graham@trevorgraham.bsky.social · last yr.

This means "adaptive therapy" where chemo dose is reduced when the tumour responds well could be a route to long-term tumour control for ovarian cancer (for certain disease types and stages). @mlockley.bsky.social is testing this in the ACTOv clinical trial: bmjopen.bmj.com/content/14/1...

Study protocol for Adaptive ChemoTherapy for Ovarian cancer (ACTOv): a multicentre phase II randomised controlled trial to evaluate the efficacy of adaptive therapy (AT) with carboplatin, based on cha...

Introduction Adaptive ChemoTherapy for Ovarian cancer (ACTOv) is a phase II, multicentre, randomised controlled trial, evaluating an adaptive therapy (AT) regimen with carboplatin in women with relaps...

bmjopen.bmj.com

Barts Cancer Institute (Queen Mary University of London)@qmbci.bsky.social · last yr.

📰 Can we use the power of evolution to improve ovarian cancer survival? A surprising approach called adaptive therapy holds promise, according to findings by @mlockley.bsky.social & team at @qmul.ac.uk & @icr.ac.uk. Read more ➡️ www.bci.qmul.ac.uk/general-news... #AACR25 #medsky #oncosky🧪

Smarter chemotherapy approach could delay drug resistance in ovarian cancer - Barts Cancer Institute - Queen Mary University of London

Adaptive chemotherapy can prolong survival in lab models of ovarian cancer, according to new results. The findings could pave the way for a more effective and gentler approach to treating ovarian canc...

bci.qmul.ac.uk